BMW stays on course despite Trump's tariffs
European carmakers are still digesting a new 15% tariff agreed between the European Union and U.S. President Donald Trump, which is lower than the current rate but still poses a major obstacle to their export-focused business.
Of the deal, BMW said it assumed negotiations were ongoing, adding that its forecast included mitigating measures in response to increased tariffs.
In 2025, the group expects a tariff-related impact of around 1.25 percentage points on its automotive segment's profit margin, the company said. In the first half of the year, the impact was some 1.5 points.
In the second quarter, the EBIT margin in the segment came in at 5.4%, just missing analysts' forecast for 5.5% in a company-provided poll, but within its 2025 target range of 5.0% to 7.0%.
BMW's results come after peers Volkswagen and Mercedes-Benz reported hefty blows to their earnings and cut their outlooks.
BMW, whose biggest plant is in the United States and is the country's top auto exporter by value, has been more upbeat.
"Our footprint in the U.S. is helping us limit the impact of tariffs," CFO Walter Mertl said in a statement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Pharma CEOs downplay impact of tariffs amid rising cost concerns
Despite analyst warnings of heightened financial risk, pharma CEOs across the US and Europe remain confident that the latest US-EU trade deal and associated tariffs will have limited impact. As per a new deal between the two global economic powerhouses, the EU will pay the US a tariff rate of 15% for pharmaceuticals. Medicines are the largest European exports to the US by value, and the EU accounts for approximately 60% of all pharmaceutical imports to the US. Top-selling drugs such as AbbVie's Humira (adalimumab), MSD's Keytruda (pembrolizumab), and Novo Nordisk's Ozempic (semaglutide), for example, are manufactured in Europe and sent to the US, representing billion-dollar markets. Analysts from GlobalData's Pharma Strategic Intelligence team say that: 'Companies manufacturing pharmaceutical products in Europe will need to anticipate financial exposure when planning launches in the US due to the unfavourable gross to net dynamics, weakened pricing leverage with US payers, and slower commercial uptake as insurers reassess cost effectiveness due to the tariffs.' US President Donald Trump has had a sharp focus on the pharma industry since assuming office. Analysts predict that adding duties to incoming goods will likely elevate costs across the pharmaceutical value chain, ultimately raising drug prices for patients. The policies make for interesting analysis when combined with his desire to cut prescription prices in the country. Diederik Stadig, sector economist for TMT & healthcare at ING, wrote in a July note: 'A tariff would hurt consumers most of all, as they would feel the inflationary effect of tariffs directly when paying for prescriptions.' The European Federation of Pharmaceutical Industries and Associations (EFPIA), for example, has maintained that tariffs on medicines are ineffective. The group says such policies only hinder patient access to medicines. GlobalData also forecasts disruptions to launch planning, particularly late-stage assets with EU-based manufacturing and production planned for entry into the US. R&D budgets of pharmaceutical companies are already under pressure and the firefighting of tariffs could place additional strain on resources. CEOs signal resilience CEOs of big pharma companies, however, are maintaining a brave face despite the projected headwinds. The UK-EU trade deal announcement arrived in the middle of the pharma industry's Q2 reporting period, where execs were pressed on financial outlooks. In a Q2 earnings call, AbbVie's CEO Rob Michael said the US company is 'fairly insulated' from any tariff-related impacts in 2025, though caveated that the company would not speculate on the longer-term consequences. AstraZeneca shared the same sentiment. CEO Pascal Soriot said the British-Swedish drugmaker is 'almost self-sufficient in terms of supply,' adding that 'tariffs is not an issue that is really affecting us very much.' However, AstraZeneca is on a long list of pharma companies transferring manufacturing to the US. This includes a $4bn investment to build a new manufacturing plant in Virginia. Sanofi has outlaid $20bn to bolster US manufacturing through 2030 and Roche unveiled a similar $50bn investment strategy, to name just a couple. The team at GlobalData added: 'Ultimately, the recent US-EU trade deal has increased the level of uncertainty within the pharmaceutical industry, raising concerns on the potential of tariffs increasing past 15% in the future. 'While the full impact will take time to unfold, it will be interesting to see the adoption of different strategies on how the pharmaceutical industry looks to balance innovation, and ensuring patient access, while managing the pressures of tariffs as they unfold into a certain reality.' A critical part of the industry's future also relies on the outcome of the US government's Section 232 investigation into the drug sector. The probe, which Trump initiated to evaluate the role of medicine imports on national security, could result in further tariffs being imposed. MSD CEO Rob Davis said in the company's Q2 earnings call: 'We need to see more clarity both from the administration and just overall as to how exactly [the 15% tariff] is going to play out. It's still not clear exactly how this relates relative to the February investigation and the timing of whether these apply now or will be phased in until there's further guidance.' AbbVie's Michael said: 'We're having constructive discussions with the administration on sectoral tariffs. Clearly, the best way to motivate that is through tax incentives as well as a trade agenda that prioritises innovation. We're well positioned as a company, but we're not going to be able to really give you any details until we understand the outcome of the 232 investigation.' Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence . "Pharma CEOs downplay impact of tariffs amid rising cost concerns" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
TechCrunch
8 minutes ago
- TechCrunch
Rivian sues to sell its EVs directly in Ohio
Rivian has filed a lawsuit in Ohio to be able sell its electric vehicles directly to consumers in the state — the latest swing in a perpetual fight between up-and-coming American automakers and the entrenched and powerful dealership lobby. The company sued the registrar of Ohio's Bureau of Motor Vehicles (BMV) on Monday in federal court, claiming the state is harming consumers by blocking direct sales. Rivian is currently able to sell EVs directly to consumers in 25 states and in Washington D.C. Ohio's BMV did not immediately respond to a request for comment. 'Ohio's prohibition of Rivian's direct-sales-only business model is irrational in the extreme: it reduces competition, decreases consumer choice, and drives up consumer costs and inconvenience — all of which harm consumers — with literally no countervailing benefit,' lawyers for the company wrote in the complaint. Rivian is asking the court to allow the company to apply for a dealership license so it can sell vehicles directly. Ohio customers have to buy from Rivian vehicles from locations in other states where direct sales are allowed. The cars are then shipped to Rivian service centers within Ohio. Allowing Rivian to sell directly would not be treading new legal ground, the company argues in its complaint. Tesla has had a license to sell in Ohio since 2013 and can sell directly to consumers. What's stopping Rivian is a 2014 law passed by the state's legislature. That law, which Rivian says came after an intense lobbying effort by the Ohio Automobile Dealers Association (OADA), effectively gave Tesla a carve-out and blocked any future manufacturers from acquiring the necessary dealership licenses. (OADA did not immediately return a request for comment.) 'Consumer choice is a bedrock principle of America's economy. Ohio's archaic prohibition against the direct-sales of vehicles is unconstitutional, irrational, and harms Ohioans by reducing competition and choice and driving up costs and inconvenience,' Mike Callahan, Rivian's chief administrative officer, said in a statement. Techcrunch event Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. San Francisco | REGISTER NOW Rivian has won legal fights over direct sales before. In 2021, Rivian and Lucid Motors were granted dealership licenses to sell EVs in the state of Illinois. That state's dealer association sued to try to block Rivian and Lucid from selling directly, but ultimately failed. Lucid Motors, meanwhile, filed a lawsuit of its own in Texas in 2022 in a challenge to that state's direct-sales ban. The court ruled against Lucid earlier this year, but the company has appealed, federal court records show.
CBS News
9 minutes ago
- CBS News
European Union delays retaliatory tariffs for six months after reaching deal with the U.S.
The European Union announced Monday it would delay retaliatory tariffs on U.S. goods for six months, giving both countries time to implement the trade agreement they reached late last month. The retaliatory tariffs, which were set to go into effect on Thursday, will be delayed until at least March. On July 27, Ursula von der Leyen, the president of the European Commission and President Trump agreed to a deal that included a 15% tariff on most goods from the EU. Though the agreement does not currently include the exemptions for car parts or wine and spirits that the EU wants, it's likely to help stabilize prices. "This political agreement restores stability and predictability for citizens and businesses on both sides of the Atlantic," European Commission spokesperson for trade Olof Gill said in a statement to CBS News. The Commission said it is working with the U.S. to finalize a statement on the agreement. "With these objectives in mind, the Commission will take the necessary steps to suspend by 6 months the EU's countermeasures against the U.S., which were due to enter into force on 7 August," the spokesperson said. The pause on retaliatory tariffs will take effect Tuesday. CBS News has reached out to the White House for comment.
